Craig A Portell

14PUBLICATIONS
122CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyHaematological tumoursPreventative health careApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Feb 12, 2026
Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.

Jing Gao, Xiaohong Zhao, Qing Yin

|May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.

Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston

|Jan 08, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.

Nancy L Bartlett, Uwe Hahn, Won-Seog Kim

|Nov 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).

Simone Filosto, Saran Vardhanabhuti, Miguel A Canales

|Feb 22, 2023
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.

Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko

Pageof 3

Frequent Collaborators

5 joint publications

Jordan Carter

5 joint publications

Brad S Kahl

3 joint publications

Reem Karmali

3 joint publications

Michael E Williams